기업
Sillajen, "DMC recommends to discontinue Phase 3 Pexa-Vec trial for liver cancer"
기사입력 : 2019-08-02 09:51수정 : 2019-08-02 10:16
바이오스펙테이터 Sungmin Kim 기자
Sillajen today announced, the independent data monitoring committee(DMC) has recommended clinically discontinuing PHOCUS phase III clinical trials for liver cancer patients. PHOCUS phase III clinical trials tests Pexa-Vex plus the standard of care, Nexavar vs Nexavar only in 600 first-line liver cancer patients(NCT02562755).
Sillajen plan to discuss the recommendations of the DMC with the Food and Drug Administration (FDA).
